Skip to main content

Table 1 Baseline characteristics

From: Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

  PSA half-life categories
Non-responder (n = 22) Ultra-rapid responder (n = 82) Rapid responder (n = 104) Intermediate responder (n = 40) Slow responder (n = 69)
Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%)
Initial PSA (ng/mL) 9.6(7.7~15.2) 33.0(16.5~61.6) 23.6(12.3~47.5) 22.8(12.1~50.5) 16.0(10.2~40.9)
Immediate preoperative PSA (ng/mL) 14.3(9.6~21.1) 0.9(0.4~2.6) 2.5(0.8~6.3) 4.6(2.1~9.2) 5.4(3.7~10.4)
ADT exposure duration (days) 35.0(22.0~46.0) 51.5(37.0~78.0) 63.5(34.0~112.5) 51.5(36.0~149.5) 70.0(36.0~314.0)
PSAT½ −196.8(−912.9~ − 47.2) 11.3(9.9~12.9) 21.6(18.3~24.0) 33.4(32.4~38.6) 94.2(54.9~148.4)
Pathologic T stage II 3(13.6) 13(15.9) 21(20.2) 11(27.5) 16(23.2)
III 17(77.3) 64(78.0) 77(74.0) 29(72.5) 49(71.0)
IV 2(9.1) 5(6.1) 6(5.8) 0(0) 4(5.8)
Pathologic Gleason score ≤6 2(9.1) 2(2.4) 3(2.9) 3(7.5) 4(5.8)
7 5(22.7) 19(23.2) 43(41.3) 12(30.0) 27(39.1)
≥8 15(68.2) 61(74.4) 58(58.7) 25(62.5) 38(55.1)
CRPC No 7(31.8) 36(43.9) 61(58.7) 25(62.5) 41(59.4)
Yes 15(68.2) 46(56.1) 43(41.3) 15(37.5) 28(40.6)
Time to CRPC (months) 13.2(6.1~21.9) 16.1(8.9~27.8) 18.8(10.0~41.2) 32.8(12.6~50.0) 18.0(6.9~43.5)
  1. PSA prostate-specific antigen, IQR interquartile range, ADT androgen deprivation therapy, CRPC castration-resistant prostate cancer, PSAT ½ prostate-specific antigen half-life